A Phase 1 interventional study of GSK2857916 in Multiple Myeloma, sponsored by GlaxoSmithKline. Completed at 9 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-11.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.
Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 17th largest by enrollment, is the only one that started in 2014, is one of 11 in phase 1, and was the 1st registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
PrECOG, LLC. · Sites in United States
Ages 18–79
GlaxoSmithKline · Sites in United States, Argentina, Australia and 21 more countries
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 18+
By country, each count listing its studies:
belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 29 · Phase 3 9
First in 2014; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 79 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 49 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 49 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
42 studies in Multiple Myeloma by GlaxoSmithKline: 6 open now, 20 under way, 7 of them phase 3. Of 19 finished, 16 (84%) have results posted.
Among the 42 studies in Multiple Myeloma by GlaxoSmithKline, this one is the 18th largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2014, is one of 12 in phase 1, and was the 9th registered.
GlaxoSmithKline’s Multiple Myeloma studies by the year they started, since 2006.
4 of the studies testing belantamab mafodotin in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05853965Universitätsklinikum Hamburg-EppendorfCombination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma | 2027-04 |
| NCT03715478Canadian Myeloma Research GroupMulti-Center Study of GSK2857916 in Combination With Pomalidomide and Dex | 2027-06-01 |
| NCT05556798Memorial Sloan Kettering Cancer CenterA Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment | 2027-10 |
| NCT05208307Emory UniversityBelantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma | 2027-10-21 |
Add all 4 to your calendar (.ics) → With an account.
Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, from their registry updates:
Among GlaxoSmithKline’s 42 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety, pharmacokinetic (PK), pharmacodynamic (PD) and the therapeutic potential of GSK2857916 in subjects with multiple myeloma (MM) and lymphomas that express B cell maturation antigen (BCMA). The hypothesis is that GSK2857916 can be safely administered to subjects with MM and with BCMA positive malignancies at doses where target engagement can be demonstrated. This study will determine if adequate target engagement of BCMA receptors translates into clinical benefit for subjects with MM and BCMA positive lymphomas. The study will consists of two parts: a Part 1 dose escalation phase and a Part 2 expansion phase for safety, tolerability, PK, PD, and clinical activity testing. The study will enroll a total of approximately 80-95 subjects with relapsed/refractory MM or BCMA-expressing hematologic malignancies. The maximum dose to be administered in this trial will not exceed 5 milligram/kilogram(mg/kg).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part 2 /MM cohort; Histologically or cytologically confirmed diagnosis of: Multiple Myeloma in a subject who fulfills all of the following: has undergone stem cell transplant, or is considered transplant ineligible, has been pretreated with at least the 3 following classes of anti-myeloma drugs: alkylators, proteasome inhibitors and immunomodulators, has demonstrated progression on, or within 60 days of completion of the last therapy, and has with at least one of the following: serum M-protein >=0.5 gram (g)/decilitre (dL) (>=5 g/Litre (L)), urine M-protein >=200 milligram (mg)/24hour (h).
Serum free light chain (FLC) assay: Involved FLC level >=5 mg/dL (>=50 mg/L) and an abnormal serum FLC ratio (\<0.26 or >1.65) and proven plasmacytoma (should be measured within 28 days of Screening Visit).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive GSK2857916 intravenously over 60 minutes (one dose) every 3 weeks (21 day cycle) for a maximum of 16 cycles.
Drug: GSK2857916
Participants may receive GSK2857916 intravenously over 60 minutes (one dose) once weekly for three consecutive weeks followed by 1 week of rest (28 day cycle) for a maximum of 16 cycles.
Drug: GSK2857916
Participants will receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for up to 16 cycles.
Drug: GSK2857916
Participants may receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for a maximum of 16 cycles.
Drug: GSK2857916
A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.
Number of Participants With Serious Adverse Events (SAEs) and Common (>=5%) Non-serious Adverse Events- Part 1
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 1 Population comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916. SAEs and common (\>=5%) non-SAEs is presented.
Time frame: Up to 23.5 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (MM)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 2 MM Population comprised of all Part 2 MM participants who received at least one dose of GSK2857916. SAEs and common (\>=5%) non-SAEs is presented.
Time frame: Up to 35 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (NHL)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 2 NHL Population comprised of all Part 2 NHL participants who received at least one dose of GSK2857916. SAEs and common (\>=5%) non-SAEs is presented.
Time frame: Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Dose-limiting Toxicities (DLTs) During the Determinative Period- Part 1
An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of the following criteria:albuminuria\>=2000mgper24 hour which has been confirmed by repeat test at least7 days apart and is not considered to be related to disease progression, Grade4 neutropenia (without fever) lasting\>=7 days, febrile neutropenia lasting\>=72 hours, Grade\>=3 thrombocytopenia associated with bleeding where estimated blood loss is\>10 milliliter orGrade4 thrombocytopenia lasting\>7 days and not responding to platelet transfusions, anyGrade3 or greaternon-hematologic toxicity as described in Common National Cancer Institute-Terminology Criteria for Adverse Events version4.0 with the exception of the following Grade3 events that can be controlled within48 hours with routine supportive measures and clinically asymptomatic electrolyte abnormalities which can be corrected within48 hours and liver toxicity meeting pre-specified GSK liver stopping criteria.
Time frame: Up to Day 21 (from first dose)
Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 1
Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP), temperature (Temp) and heart rate (HR). SBP and DBP were graded using National Cancer Institute-Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. For SBP: Grade 0-\<120 millimeters of mercury\[mmHg\], 120-139 mmHg\[Grade 1\], 140-159 mmHg\[Grade 2\], \>=160 mmHg\[Grade 3\]); For DBP: \<80 mmHg \[Grade 0\], 80-89\[Grade 1\], 90-99\[Grade 2\], \>=100 mmHg\[Grade 3\]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time frame: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (MM)
Vital signs included SBP, DBP, Temp and HR. SBP and DBP were graded using NCI CTCAE version 4.0. For SBP: Grade 0-\<120 mmHg, 120-139 mmHg\[Grade 1\], 140-159 mmHg\[Grade 2\], \>=160 mmHg\[Grade 3\]); For DBP: \<80 mmHg \[Grade 0\], 80-89\[Grade 1\], 90-99\[Grade 2\], \>=100 mmHg\[Grade 3\]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time frame: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (NHL)
Vital signs included SBP, DBP, Temp and HR. SBP and DBP were graded using NCI CTCAE version 4.0. For SBP: Grade 0-\<120 mmHg, 120-139 mmHg \[Grade 1\], 140-159 mmHg\[Grade 2\], \>=160 mmHg \[Grade 3\]); For DBP: \<80 mmHg \[Grade 0\], 80-89\[Grade 1\], 90-99\[Grade 2\], \>=100 mmHg\[Grade 3\]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time frame: Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 1
The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to \<60 beats per minute \[bpm\] and increase to \>100 bpm) and change in temperature from Baseline (increase to \>=38 or decrease to \<=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time frame: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (MM)
The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to \<60 bpm and increase to \>100 bpm) and change in temperature from Baseline(increase to \>=38 or decrease to \<=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time frame: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (NHL)
The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to \<60 bpm and increase to \>100 bpm) and change in temperature from Baseline(increase to \>=38 or decrease to \<=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time frame: Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Blood samples were collected for the analysis of following clinical chemistry parameters: albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (T.Bil.), calcium (Ca), creatinine (Creat), creatinine kinase (CK), gamma glutamyl transferase (GGT), glucose (Gl), potassium (Pot), magnesium (Mg), sodium (Sod), phosphate (Ph) and urate. Values(Hyper and hypo)for Gl, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time frame: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Blood samples were collected for the analysis of following clinical chemistry parameters: albumin,ALP,ALT,AST,T.Bil.,Ca, Creat,CK, GGT,Gl, Pot,Mg, Sod, Ph and urate. Values(Hyper and hypo)for Gl, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time frame: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Blood samples were collected for the analysis of following clinical chemistry parameters: albumin, ALP, ALT, AST, Bilirubin, Ca, Creat, CK, GGT, Glucose, Pot, Mg, Sod, and Ph. Values(Hyper and hypo)for Glucose, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time frame: Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
Blood samples were collected for the analysis of following clinical chemistry parameters: direct bilirubin (D.Bil.), chloride, carbon dioxide (CO2), lactate dehydrogenase (LDH), total protein (T.Pro) and urea or blood urea nitrogen (BUN). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or No Change (NC)' category. Participants were counted twice if the participant "Decreased to low" and "Increased to high" during post-Baseline. Data for worst-case post Baseline is presented.
Time frame: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
Blood samples were collected for the analysis of following clinical chemistry parameters: D.Bil., chloride, CO2, LDH, T.Pro and BUN. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data for worst-case post Baseline is presented.
Time frame: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)
Blood samples were collected for the analysis of following clinical chemistry parameters: D.Bil., chloride, CO2, LDH, and T.Pro. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline. Data for worst-case post Baseline is presented.
Time frame: Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Blood samples were collected for the analysis of following hematology parameters: hemoglobin (Hb), lymphocytes (Lymph), neutrophils (Neutro), platelet count (PC), and leukocytes (leuko). The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.
Time frame: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Blood samples were collected for the analysis of following hematology parameters: Hb, Lymph, Neutro, PC, and leuko. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits.An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.
Time frame: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Blood samples were collected for the analysis of following hematology parameters: Hb, Lymph, Neutro, PC, and leuko. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.
Time frame: Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Blood samples were collected for the analysis of following hematology parameters: basophils (Baso), eosinophils (Eosino), hematocrit (Hct), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), monocytes (Mono), erythrocytes (Erythro) and reticulocytes (Reticu). A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data at worst-case post Baseline is presented.
Time frame: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Blood samples were collected for the analysis of following hematology parameters: Baso, Eosino, Hct, MCHC, MCH, MCV, Mono, Erythro and Reticu. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data at worst-case post Baseline is presented.
Time frame: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Blood samples were collected for the analysis of following hematology parameters: Baso, Eosino, Hct, MCHC, MCH, MCV, Mono, Erythro and Reticu. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline. Data at worst-case post Baseline is presented.
Time frame: Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 1
Urine samples were collected to assess urine occult blood (OB) and urine protein (Pro). The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB and no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ for urine Pro indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time frame: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (MM)
Urine samples were collected to assess urine OB and urine Pro. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB and no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ for urine Pro indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time frame: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (NHL)
Urine samples were collected to assess urine OB and urine Pro. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB. For Urine Pro., results were reported as no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Time frame: Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.06 mg/kg
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Time frame: Baseline and Day 1 (Cycle 2 and 3)
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.03 mg/kg and 0.12 mg/kg
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Time frame: Baseline and Day 1 (Cycle 2)
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Time frame: Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13,14, 15)
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.48 mg/kg
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Time frame: Baseline and Day 1 (Cycle 2, 3, 5, 6, 7, 8)
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.96 mg/kg
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Time frame: Baseline and Day 1 (Cycle 2, 3, 4, 5, 6)
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Time frame: Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 14, 16)
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Time frame: Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, 14, 15, 16)
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Time frame: Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Time frame: Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (NHL)
Urine samples were collected to assess urine Protein. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Protein excretion (24 hour) is presented.
Time frame: Baseline and Day 1 (Cycle 2)
Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1
Blood samples were collected at designated timepoints. Pharmacokinetic (PK) parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time frame: Pre-dose, 30 minutes post start of infusion (SOI), at end of infusion (EOI), 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
AUC[0-infinity] of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time frame: Pre-dose and EOI of Day 1 (Cycle 1)
Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
AUC[0-tau] of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time frame: Pre-dose and EOI of Day 1 (Cycle 1)
Area Under the Concentration-time Curve From Zero to Time of Last Quantifiable Concentration (AUC[0-tlast]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
AUC[0-tlast]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time frame: Pre-dose and EOI of Day 1 (Cycle 1)
Clearance (CL) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
CL of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time frame: Pre-dose and EOI of Day 1 (Cycle 1)
Maximum Observed Concentration (Cmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
Cmax of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time frame: Pre-dose and EOI of Day 1 (Cycle 1)
Trough Plasma Concentration (Ctrough) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1), Pre-dose and EOI of Day 1 (Cycle 2 and Cycle 4)
Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time frame: Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)
Terminal Half-life (t1/2) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
t1/2 of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time frame: Pre-dose and EOI of Day 1 (Cycle 1)
Volume of Distribution at Steady State (Vss) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
Vss of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time frame: Pre-dose and EOI of Day 1 (Cycle 1)
Time to Reach Maximum Observed Concentration (Tmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. Median and full range of Tmax have been presented.
Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
Tmax of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. Median and full range of Tmax have been presented.
Time frame: Pre-dose and EOI of Day 1 (Cycle 1)
Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM-Part 2
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time frame: Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)
Ctrough of GSK2857916 Following IV Dose in Participants With NHL-Part 2
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Time frame: Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 3)
AUC(0-tlast) of Cys Monomethyl Auristatin F (Cys-mcMMAF) Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
AUC(0-tlast) of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.
Time frame: Pre-dose and EOI of Day 1 (Cycle 1)
Cmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
Cmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.
Time frame: Pre-dose and EOI of Day 1 (Cycle 1)
Ctrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1), Pre-dose and EOI of Day 1 (Cycle 2 and Cycle 4)
Ctrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Time frame: Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)
Tmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. Median and full range of Tmax have been presented.
Time frame: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)
Tmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM-Part 1: GSK2857916 2.50 mg/kg
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. Median and full range of Tmax have been presented.
Time frame: Pre-dose and EOI of Day 1 (Cycle 1)
Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 1
Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated electrochemiluminescent (ECL) immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.
Time frame: Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (MM)
Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.
Time frame: Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (NHL)
Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated ECLimmunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.
Time frame: Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive (pos) samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative (neg) conclusive ADA results at Baseline and different timepoints is presented.
Time frame: Baseline, Day 1 (Cycle 2, 3, 4, 6, 9, 12, 16), End of study (within 30 days [+ 7 days of last treatment or prior to the start of new anti-cancer treatment], whichever is earlier) (1 cycle=21 days)
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative conclusive ADA results at Baseline and different timepoints is presented.
Time frame: Baseline, Day 1 (Cycle 2, 3, 6, 7, 9, 11, 12, 16), End of study (within 30 days [+ 7 days of last treatment or prior to the start of new anti-cancer treatment], whichever is earlier) (1 cycle=21 days)
Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)
Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative conclusive ADA results at Baseline and different timepoints is presented.
Time frame: Baseline, Day 1 (Cycle 2, 3), End of study (within 30 days [+ 7 days of last treatment or prior to the start of new anti-cancer treatment], whichever is earlier) (1 cycle=21 days)
Overall Response Rate (ORR)- Part 1
ORR was determined by the investigator according to international myeloma working group uniform response criteria for MM (IMWG 2011). ORR was calculated as the number of participants with best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) and partial response (PR).
Time frame: From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 21.6 months)
ORR-Part 2 (MM)
ORR was determined by the investigator according to IMWG 2011 uniform response criteria for MM. ORR was calculated as the number of participants with best overall response of sCR, CR, VGPR and PR.
Time frame: From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 24.2 months)
ORR-Part 2 (NHL)
Overall Response Rate in NHL population was determined by the investigator according to Revised Response Criteria for Malignant Lymphoma. ORR was calculated as the number of participants with confirmed complete remission (CR) or partial remission (PR). Complete remission was defined as disappearance of all evidence of disease and partial remission was defined as regression of measurable disease and no new sites.
Time frame: From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 7.2 months)
Clinical Benefit Rate (CBR)- Part 1
CBR was calculated as the number of participants with best overall response of sCR, CR, VGPR, PR and minimal response (MR).
Time frame: From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 21.6 months)
CBR- Part 2
CBR was calculated as the number of participants with best overall response of sCR, CR, VGPR, PR and MR.
Time frame: From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 24.2 months)
This is a Phase1 study of antibody drug conjugate GSK2857916 in participants with relapsed/refractory multiple myeloma(MM) or non-hodgkin's lymphoma (NHL).The study was conducted in 2 parts-Part1(dose escalation) and Part2(dose expansion).The starting dose in Part1 was 0.03mg/kg GSK2857916 given once every three weeks; 1cycle=21 days for 16cycles.
| Milestone | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg | Part 2: GSK2857916 3.40 mg/kg (MM) | Part 2: GSK2857916 3.40 mg/kg (NHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 4 | 4 | 4 | 3 | 4 | 8 | 3 | 6 | 0 | 0 |
| Completed | 1 | 1 | 4 | 4 | 4 | 3 | 4 | 6 | 2 | 5 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg | Part 2: GSK2857916 3.40 mg/kg (MM) | Part 2: GSK2857916 3.40 mg/kg (NHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 35 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 29 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 3 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 1 Population comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916. SAEs and common (\>=5%) non-SAEs is presented.
| Participants | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| Common non-SAE | 1 | 1 | 4 | 4 | 3 | 3 | 4 | 8 | 3 | 6 |
| Any SAE | 0 | 0 | 1 | 1 | 1 | 0 | 2 | 4 | 1 | 3 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 2 MM Population comprised of all Part 2 MM participants who received at least one dose of GSK2857916. SAEs and common (\>=5%) non-SAEs is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (MM) |
|---|---|
| Common non-SAE | 35 |
| Any SAE | 17 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 2 NHL Population comprised of all Part 2 NHL participants who received at least one dose of GSK2857916. SAEs and common (\>=5%) non-SAEs is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (NHL) |
|---|---|
| Common non-SAE | 6 |
| Any SAE | 3 |
An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of the following criteria:albuminuria\>=2000mgper24 hour which has been confirmed by repeat test at least7 days apart and is not considered to be related to disease progression, Grade4 neutropenia (without fever) lasting\>=7 days, febrile neutropenia lasting\>=72 hours, Grade\>=3 thrombocytopenia associated with bleeding where estimated blood loss is\>10 milliliter orGrade4 thrombocytopenia lasting\>7 days and not responding to platelet transfusions, anyGrade3 or greaternon-hematologic toxicity as described in Common National Cancer Institute-Terminology Criteria for Adverse Events version4.0 with the exception of the following Grade3 events that can be controlled within48 hours with routine supportive measures and clinically asymptomatic electrolyte abnormalities which can be corrected within48 hours and liver toxicity meeting pre-specified GSK liver stopping criteria.
| Participants | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLTs) During the Determinative Period- Part 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP), temperature (Temp) and heart rate (HR). SBP and DBP were graded using National Cancer Institute-Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. For SBP: Grade 0-\<120 millimeters of mercury\[mmHg\], 120-139 mmHg\[Grade 1\], 140-159 mmHg\[Grade 2\], \>=160 mmHg\[Grade 3\]); For DBP: \<80 mmHg \[Grade 0\], 80-89\[Grade 1\], 90-99\[Grade 2\], \>=100 mmHg\[Grade 3\]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
| Participants | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| DBP, any grade increase | 0 | 1 | 2 | 1 | 2 | 3 | 3 | 5 | 3 | 4 |
| SBP, any grade increase | 0 | 1 | 2 | 2 | 3 | 1 | 3 | 7 | 2 | 5 |
Vital signs included SBP, DBP, Temp and HR. SBP and DBP were graded using NCI CTCAE version 4.0. For SBP: Grade 0-\<120 mmHg, 120-139 mmHg\[Grade 1\], 140-159 mmHg\[Grade 2\], \>=160 mmHg\[Grade 3\]); For DBP: \<80 mmHg \[Grade 0\], 80-89\[Grade 1\], 90-99\[Grade 2\], \>=100 mmHg\[Grade 3\]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (MM) |
|---|---|
| DBP, any grade increase | 30 |
| SBP, any grade increase | 31 |
Vital signs included SBP, DBP, Temp and HR. SBP and DBP were graded using NCI CTCAE version 4.0. For SBP: Grade 0-\<120 mmHg, 120-139 mmHg \[Grade 1\], 140-159 mmHg\[Grade 2\], \>=160 mmHg \[Grade 3\]); For DBP: \<80 mmHg \[Grade 0\], 80-89\[Grade 1\], 90-99\[Grade 2\], \>=100 mmHg\[Grade 3\]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (NHL) |
|---|---|
| DBP, any grade increase | 5 |
| SBP, any grade increase | 5 |
The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to \<60 beats per minute \[bpm\] and increase to \>100 bpm) and change in temperature from Baseline (increase to \>=38 or decrease to \<=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
| Participants | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| HR, decrease to <60 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 4 | 1 | 3 |
| HR, change to normal or no change | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 3 | 1 | 1 |
| HR, increase to >100 | 1 | 1 | 2 | 1 | 3 | 3 | 2 | 1 | 1 | 2 |
| Temp, decrease to <=35 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Temp, change to normal or no change | 1 | 1 | 3 | 4 | 4 | 2 | 4 | 8 | 2 | 6 |
| Temp, increase to >=38 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to \<60 bpm and increase to \>100 bpm) and change in temperature from Baseline(increase to \>=38 or decrease to \<=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (MM) |
|---|---|
| HR, decrease to <60 | 9 |
| HR, change to normal or no change | 17 |
| HR, increase to >100 | 10 |
| Temp, decrease to <=35 | 1 |
| Temp, change to normal or no change | 29 |
| Temp, increase to >=38 | 5 |
The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to \<60 bpm and increase to \>100 bpm) and change in temperature from Baseline(increase to \>=38 or decrease to \<=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (NHL) |
|---|---|
| HR, decrease to <60 | 3 |
| HR, change to normal or no change | 2 |
| HR, increase to >100 | 1 |
| Temp, decrease to <=35 | 0 |
| Temp, change to normal or no change | 5 |
| Temp, increase to >=38 | 1 |
Blood samples were collected for the analysis of following clinical chemistry parameters: albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (T.Bil.), calcium (Ca), creatinine (Creat), creatinine kinase (CK), gamma glutamyl transferase (GGT), glucose (Gl), potassium (Pot), magnesium (Mg), sodium (Sod), phosphate (Ph) and urate. Values(Hyper and hypo)for Gl, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
| Participants | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| Gl, Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 1 | 1 | 4 | 0 | 4 | 6 | 0 | 4 |
| Gl, Hyper,increase toGrade 3,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Gl, Hyper,increase toGrade 4,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gl, Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 2 |
| Gl, Hypo,increase toGrade 3,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gl, Hypo,increase toGrade 4,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Albumin,any grade increase,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 2 |
| Albumin,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Albumin,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALP,any grade increase,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 2 | 2 | 5 |
| ALP,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALP,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT,any grade increase,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 1 | 2 | 1 | 0 | 1 | 5 | 1 | 5 |
| ALT,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST,any grade increase,n=1,1,4,4,4,3,4,8,3,6 | 0 | 1 | 2 | 2 | 1 | 1 | 3 | 6 | 3 | 5 |
| AST,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| T.Bil.,any grade increase,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| T.Bil.,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| T.Bil.,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CK,any grade increase,n=1,1,4,4,3,3,4,8,3,6 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 3 | 3 |
| CK,increase to Grade 3,n=1,1,4,4,3,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| CK,increase to Grade 4,n=1,1,4,4,3,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creat,any grade increase,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Creat,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creat,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GGT,any grade increase,1,1,4,4,3,3,4,8,3,6 | 0 | 0 | 1 | 1 | 1 | 0 | 3 | 3 | 3 | 4 |
| GGT,increase to Grade 3,n=1,1,4,4,3,3,4,8,3,6 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| GGT,increase to Grade 4,n=1,1,4,4,3,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pot,Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pot,Hyper,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pot,Hyper,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pot,Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 2 |
| Pot,Hypo,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pot,Hypo,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mg,Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mg,Hyper,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mg,Hyper,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mg,Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 3 | 0 | 3 |
| Mg,Hypo,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mg,Hypo,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ph,any grade increase,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Ph,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ph,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sod,Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Sod,Hyper,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sod,Hyper,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sod,Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,6 | 0 | 1 | 1 | 2 | 2 | 1 | 3 | 2 | 0 | 3 |
| Sod,Hypo,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Sod,Hypo,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urate,any grade increase,n=1,1,4,4,4,3,4,8,3,6 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Urate,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urate,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Ca,Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 1 | 0 | 1 | 1 | 3 | 2 | 0 | 1 |
| Ca,Hyper,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Ca,Hyper,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ca,Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| Ca,Hypo,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ca,Hypo,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected for the analysis of following clinical chemistry parameters: albumin,ALP,ALT,AST,T.Bil.,Ca, Creat,CK, GGT,Gl, Pot,Mg, Sod, Ph and urate. Values(Hyper and hypo)for Gl, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (MM) |
|---|---|
| Gl, Hyperglycemia,any grade increase,n=35 | 19 |
| Gl, Hyperglycemia,increase to Grade 3,n=35 | 0 |
| Gl, Hyperglycemia,increase to Grade 4,n=35 | 0 |
| Gl, Hypoglycemia,any grade increase,n=35 | 1 |
| Gl, Hypoglycemia,increase to Grade 3,n=35 | 0 |
| Gl, Hypoglycemia,increase to Grade 4,n=35 | 0 |
| Albumin,any grade increase,n=35 | 15 |
| Albumin,increase to Grade 3,n=35 | 2 |
| Albumin,increase to Grade 4,n=35 | 0 |
| ALP,any grade increase,n=35 | 19 |
| ALP,increase to Grade 3,n=35 | 0 |
| ALP,increase to Grade 4,,n=35 | 0 |
| ALT,any grade increase,n=35 | 19 |
| ALT,increase to Grade 3,n=35 | 0 |
| ALT,increase to Grade 4,n=35 | 0 |
| AST,any grade increase,n=35 | 29 |
| AST,increase to Grade 3,n=35 | 3 |
| AST,increase to Grade 4,n=35 | 0 |
| Total bilirubin,any grade increase,n=35 | 3 |
| Total bilirubin,increase to Grade 3,n=35 | 0 |
| Total bilirubin,increase to Grade 4,n=35 | 0 |
| CK,any grade increase,n=35 | 15 |
| CK,increase to Grade 3,n=35 | 1 |
| CK,increase to Grade 4 ,n=35 | 0 |
| Creatinine,any grade increase,n=35 | 7 |
| Creatinine,increase to Grade 3,n=35 | 0 |
| Creatinine,increase to Grade 4,n=35 | 0 |
| GGT,any grade increase,n=34 | 21 |
| GGT,increase to Grade 3,n=34 | 6 |
| GGT,increase to Grade 4,n=34 | 0 |
| Pot,Hyperkalemia,any grade increase,n=35 | 1 |
| Pot,Hyperkalemia,increase to Grade 3,n=35 | 0 |
| Pot,Hyperkalemia,increase to Grade 4,n=35 | 1 |
| Pot,Hypokalemia,any grade increase,n=35 | 12 |
| Pot,Hypokalemia,increase to Grade 3,n=35 | 3 |
| Pot,Hypokalemia,increase to Grade 4,n=35 | 1 |
| Mg,Hypermagnesemia,any grade increase,n=34 | 1 |
| Mg,Hypermagnesemia,increase to Grade 3,n=34 | 0 |
| Mg,Hypermagnesemia,increase to Grade 4,n=34 | 0 |
| Mg,Hypomagnesemia,any grade increase,n=34 | 9 |
| Mg,Hypomagnesemia,increase to Grade 3,n=34 | 0 |
| Mg,Hypomagnesemia,increase to Grade 4,n=34 | 1 |
| Phosphate,any grade increase,n=35 | 8 |
| Phosphate,increase to Grade 3,n=35 | 0 |
| Phosphate,increase to Grade 4,n=35 | 0 |
| Sod,Hypernatremia,any grade increase,n=35 | 0 |
| Sod,Hypernatremia,increase to Grade 3,n=35 | 0 |
| Sod,Hypernatremia,increase to Grade 4,n=35 | 0 |
| Sod,Hyponatremia,any grade increase,n=35 | 4 |
| Sod,Hyponatremia,increase to Grade 3,n=35 | 0 |
| Sod,Hyponatremia,increase to Grade 4,n=35 | 1 |
| Urate,any grade increase,n=35 | 1 |
| Urate,increase to Grade 3,n=35 | 0 |
| Urate,increase to Grade 4,n=35 | 1 |
| Ca,Hypercalcemia,any grade increase,n=35 | 8 |
| Ca,Hypercalcemia,increase to Grade 3,n=35 | 2 |
| Ca,Hypercalcemia,increase to Grade 4,,n=35 | 1 |
| Ca,Hypocalcemia,any grade increase,n=35 | 4 |
| Ca,Hypocalcemia,increase to Grade 3,n=35 | 0 |
| Ca,Hypocalcemia,increase to Grade 4,n=35 | 0 |
Blood samples were collected for the analysis of following clinical chemistry parameters: albumin, ALP, ALT, AST, Bilirubin, Ca, Creat, CK, GGT, Glucose, Pot, Mg, Sod, and Ph. Values(Hyper and hypo)for Glucose, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (NHL) |
|---|---|
| Gl, Hyperglycemia,any grade increase | 2 |
| Gl, Hyperglycemia,increase to Grade 3 | 0 |
| Gl, Hyperglycemia,increase to Grade 4 | 0 |
| Gl, Hypoglycemia,any grade increase | 0 |
| Gl, Hypoglycemia,increase to Grade 3 | 0 |
| Gl, Hypoglycemia,increase to Grade 4 | 0 |
| Albumin,any grade increase | 2 |
| Albumin,increase to Grade 3 | 0 |
| Albumin,increase to Grade 4 | 0 |
| ALP,any grade increase | 1 |
| ALP,increase to Grade 3 | 0 |
| ALP,increase to Grade 4 | 0 |
| ALT,any grade increase | 1 |
| ALT,increase to Grade 3 | 0 |
| ALT,increase to Grade 4 | 0 |
| AST,any grade increase | 2 |
| AST,increase to Grade 3 | 0 |
| AST,increase to Grade 4 | 0 |
| Total bilirubin,any grade increase | 2 |
| Total bilirubin,increase to Grade 3 | 0 |
| Total bilirubin,increase to Grade 4 | 0 |
| CK,any grade increase | 1 |
| CK,increase to Grade 3 | 0 |
| CK,increase to Grade 4 | 0 |
| Creatinine,any grade increase | 1 |
| Creatinine,increase to Grade 3 | 0 |
| Creatinine,increase to Grade 4 | 0 |
| GGT,any grade increase | 2 |
| GGT,increase to Grade 3 | 0 |
| GGT,increase to Grade 4 | 0 |
| Pot,Hyperkalemia,any grade increase | 0 |
| Pot,Hyperkalemia,increase to Grade 3 | 0 |
| Pot,Hyperkalemia,increase to Grade 4 | 0 |
| Pot,Hypokalemia,any grade increase | 1 |
| Pot,Hypokalemia,increase to Grade 3 | 0 |
| Pot,Hypokalemia,increase to Grade 4 | 0 |
| Mg,Hypermagnesemia,any grade increase | 0 |
| Mg,Hypermagnesemia,increase to Grade 3 | 0 |
| Mg,Hypermagnesemia,increase to Grade 4 | 0 |
| Mg,Hypomagnesemia,any grade increase | 1 |
| Mg,Hypomagnesemia,increase to Grade 3 | 0 |
| Mg,Hypomagnesemia,increase to Grade 4 | 0 |
| Phosphate,any grade increase | 2 |
| Phosphate,increase to Grade 3 | 1 |
| Phosphate,increase to Grade 4 | 0 |
| Sod,Hypernatremia,any grade increase | 0 |
| Sod,Hypernatremia,increase to Grade 3 | 0 |
| Sod,Hypernatremia,increase to Grade 4 | 0 |
| Sod,Hyponatremia,any grade increase | 3 |
| Sod,Hyponatremia,increase to Grade 3 | 0 |
| Sod,Hyponatremia,increase to Grade 4 | 0 |
| Ca,Hypercalcemia,any grade increase | 4 |
| Ca,Hypercalcemia,increase to Grade 3 | 1 |
| Ca,Hypercalcemia,increase to Grade 4 | 0 |
| Ca,Hypocalcemia,any grade increase | 1 |
| Ca,Hypocalcemia,increase to Grade 3 | 0 |
| Ca,Hypocalcemia,increase to Grade 4 | 0 |
Blood samples were collected for the analysis of following clinical chemistry parameters: direct bilirubin (D.Bil.), chloride, carbon dioxide (CO2), lactate dehydrogenase (LDH), total protein (T.Pro) and urea or blood urea nitrogen (BUN). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or No Change (NC)' category. Participants were counted twice if the participant "Decreased to low" and "Increased to high" during post-Baseline. Data for worst-case post Baseline is presented.
| Participants | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| D.Bil.,decrease to low,n=1,1,4,2,2,3,4,4,3,5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| D.Bil.,to normal or NC, n=1,1,4,2,2,3,4,4,3,5 | 1 | 1 | 3 | 2 | 1 | 3 | 4 | 3 | 3 | 3 |
| D.Bil.,increase to high,n=1,1,4,2,2,3,4,4,3,5 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Chloride,decrease to low,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 3 | 0 | 3 |
| Chloride,to normal or NC,n=1,1,4,4,4,3,4,8,3,6 | 1 | 1 | 3 | 4 | 2 | 2 | 3 | 4 | 2 | 3 |
| Chloride,increase to high,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| CO2,decrease to low,n=1,1,4,4,4,3,4,8,3,6 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 2 | 2 | 2 |
| CO2, to normal or NC,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 3 | 1 | 3 | 2 | 0 | 5 | 1 | 4 |
| CO2,increase to high,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| LDH,decrease to low,n=1,1,4,4,3,3,4,8,3,6 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| LDH,to normal or NC,n=n=1,1,4,4,3,3,4,8,3,6 | 1 | 1 | 2 | 2 | 1 | 2 | 1 | 5 | 1 | 1 |
| LDH,increase to high,n=1,1,4,4,3,3,4,8,3,6 | 0 | 0 | 2 | 1 | 1 | 1 | 3 | 3 | 2 | 5 |
| T.Pro,decrease to low,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 2 | 0 |
| T.Pro,to normal or NC,n=1,1,4,4,4,3,4,8,3,6 | 1 | 1 | 4 | 3 | 2 | 2 | 3 | 6 | 1 | 4 |
| T.Pro,increase to high,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 2 |
| BUN,decrease to low,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 1 | 0 | 2 |
| BUN,to normal or NC,n=1,1,4,4,4,3,4,8,3,6 | 1 | 1 | 2 | 3 | 2 | 3 | 3 | 5 | 2 | 3 |
| BUN,increase to high,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 2 | 1 | 1 |
Blood samples were collected for the analysis of following clinical chemistry parameters: D.Bil., chloride, CO2, LDH, T.Pro and BUN. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data for worst-case post Baseline is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (MM) |
|---|---|
| D.Bil.,decrease to low,n=30 | 2 |
| D.Bil., to normal or no change,n=30 | 20 |
| D.Bil.,increase to high,n=30 | 8 |
| Chloride,decrease to low,n=35 | 7 |
| Chloride, to normal or no change,n=35 | 25 |
| Chloride,increase to high,n=35 | 4 |
| CO2,decrease to low,n=35 | 8 |
| CO2, to normal or no change,n=35 | 23 |
| CO2,increase to high,n=35 | 5 |
| LDH,decrease to low,n=35 | 1 |
| LDH, to normal or no change,n=35 | 17 |
| LDH,increase to high,n=35 | 17 |
| T.Pro,decrease to low,n=35 | 11 |
| T.Pro, to normal or no change,n=35 | 18 |
| T.Pro,increase to high,n=35 | 7 |
| BUN,decrease to low,n=35 | 8 |
| BUN, to normal or no change,n=35 | 23 |
| BUN,increase to high,n=35 | 4 |
Blood samples were collected for the analysis of following clinical chemistry parameters: D.Bil., chloride, CO2, LDH, and T.Pro. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline. Data for worst-case post Baseline is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (NHL) |
|---|---|
| D.Bil.,decrease to low,n=2 | 0 |
| D.Bil., to normal or no change,n=2 | 2 |
| D.Bil.,increase to high,n=2 | 0 |
| Chloride,decrease to low,n=5 | 1 |
| Chloride, to normal or no change,n=5 | 2 |
| Chloride,increase to high,n=5 | 2 |
| CO2,decrease to low,n=5 | 2 |
| CO2, to normal or no change,n=5 | 3 |
| CO2,increase to high,n=5 | 0 |
| LDH,decrease to low,n=5 | 0 |
| LDH, to normal or no change,n=5 | 4 |
| LDH,increase to high,n=5 | 1 |
| T.Pro,decrease to low,n=5 | 1 |
| T.Pro, to normal or no change,n=5 | 4 |
| T.Pro,increase to high,n=5 | 0 |
Blood samples were collected for the analysis of following hematology parameters: hemoglobin (Hb), lymphocytes (Lymph), neutrophils (Neutro), platelet count (PC), and leukocytes (leuko). The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.
| Participants | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| Hb, Hb increased, any grade increase | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Hb, Hb increased, increase to Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hb, Hb increased, increase to Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hb,Anemia, any grade increase | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 3 | 2 | 4 |
| Hb, Anemia, increase to Grade 3 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 |
| Hb, Anemia, increase to Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymph, Lymph count increased, any grade increase | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymph, Lymph count increased, increase to Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymph, Lymph count increased, increase to Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymph, Lymph count decreased, any grade increase | 0 | 0 | 1 | 0 | 2 | 1 | 2 | 4 | 2 | 3 |
| Lymph, Lymph count decreased, increase to Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 1 |
| Lymph, Lymph count decreased, increase to Grade 4 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Neutro, any grade increase | 1 | 1 | 2 | 1 | 0 | 2 | 1 | 4 | 2 | 3 |
| Neutro, increase to Grade 3 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Neutro, increase to Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| PC, any grade increase | 1 | 1 | 2 | 3 | 1 | 1 | 2 | 6 | 3 | 6 |
| PC, increase to Grade 3 | 1 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 2 | 4 |
| PC, increase to Grade 4 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Leuko, Leukocytosis, any grade increase | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leuko, Leukocytosis, increase to Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leuko, Leukocytosis, increase to Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leuko, Leuko decreased, any grade increase | 1 | 1 | 3 | 1 | 1 | 1 | 3 | 1 | 2 | 3 |
| Leuko, Leuko decreased, increase to Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Leuko, Leuko decreased, increase to Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected for the analysis of following hematology parameters: Hb, Lymph, Neutro, PC, and leuko. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits.An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (MM) |
|---|---|
| Hb, Hb increased, any grade increase | 1 |
| Hb, Hb increased, increase to Grade 3 | 0 |
| Hb, Hb increased, increase to Grade 4 | 0 |
| Hb,Anemia, any grade increase | 18 |
| Hb, Anemia, increase to Grade 3 | 7 |
| Hb, Anemia, increase to Grade 4 | 0 |
| Lymph, Lymph count increased, any grade increase | 3 |
| Lymph, Lymph count increased, increase to Grade 3 | 0 |
| Lymph, Lymph count increased, increase to Grade 4 | 0 |
| Lymph, Lymph count decreased, any grade increase | 18 |
| Lymph, Lymph count decreased, increase to Grade 3 | 8 |
| Lymph, Lymph count decreased, increase to Grade 4 | 2 |
| Neutro, any grade increase | 15 |
| Neutro, increase to Grade 3 | 2 |
| Neutro, increase to Grade 4 | 5 |
| PC, any grade increase | 32 |
| PC, increase to Grade 3 | 13 |
| PC, increase to Grade 4 | 3 |
| Leuko, Leukocytosis, any grade increase | 0 |
| Leuko, Leukocytosis, increase to Grade 3 | 0 |
| Leuko, Leukocytosis, increase to Grade 4 | 0 |
| Leuko, Leuko decreased, any grade increase | 16 |
| Leuko, Leuko decreased, increase to Grade 3 | 4 |
| Leuko, Leuko decreased, increase to Grade 4 | 1 |
Blood samples were collected for the analysis of following hematology parameters: Hb, Lymph, Neutro, PC, and leuko. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (NHL) |
|---|---|
| Hb, Hb increased, any grade increase, n=6 | 0 |
| Hb, Hb increased, increase to Grade 3, n=6 | 0 |
| Hb, Hb increased, increase to Grade 4, n=6 | 0 |
| Hb,Anemia, any grade increase, n=6 | 2 |
| Hb, Anemia, increase to Grade 3, n=6 | 0 |
| Hb, Anemia, increase to Grade 4, n=6 | 0 |
| Lymph,Lymph count increased,any grade increase,n=6 | 0 |
| Lymph,Lymph count increased,increase to Grade3,n=6 | 0 |
| Lymph,Lymph count increased,increase to Grade4,n=6 | 0 |
| Lymph,Lymph count decreased,any grade increase,n=6 | 5 |
| Lymph,Lymph count decreased,increase to Grade3,n=6 | 3 |
| Lymph,Lymph count decreased,increase to Grade4,n=6 | 2 |
| Neutro, any grade increase, n=6 | 0 |
| Neutro, increase to Grade 3, n=6 | 0 |
| Neutro, increase to Grade 4, n=6 | 0 |
| PC, any grade increase, n=5 | 3 |
| PC, increase to Grade 3, n=5 | 0 |
| PC, increase to Grade 4, n=5 | 1 |
| Leuko, Leukocytosis, any grade increase, n=6 | 0 |
| Leuko, Leukocytosis, increase to Grade 3, n=6 | 0 |
| Leuko, Leukocytosis, increase to Grade 4, n=6 | 0 |
| Leuko, Leuko decreased, any grade increase, n=6 | 4 |
| Leuko, Leuko decreased, increase to Grade 3, n=6 | 0 |
| Leuko, Leuko decreased, increase to Grade 4, n=6 | 0 |
Blood samples were collected for the analysis of following hematology parameters: basophils (Baso), eosinophils (Eosino), hematocrit (Hct), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), monocytes (Mono), erythrocytes (Erythro) and reticulocytes (Reticu). A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data at worst-case post Baseline is presented.
| Participants | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| Baso,decrease to low,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Baso, to normal or NC,n=1,1,4,4,4,3,4,8,3,6 | 1 | 1 | 4 | 4 | 4 | 3 | 3 | 8 | 3 | 3 |
| Baso,increase to high,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 |
| Eosino,decrease to low,n=1,1,4,4,4,3,4,8,3,6 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Eosino,to normal or NC,n=1,1,4,4,4,3,4,8,3,6 | 0 | 1 | 3 | 4 | 4 | 2 | 4 | 8 | 3 | 4 |
| Eosino,increase to high,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Hct,decrease to low,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 |
| Hct, to normal or NC,n=1,1,4,4,4,3,4,8,3,6 | 1 | 1 | 4 | 3 | 4 | 2 | 4 | 7 | 1 | 6 |
| Hct,increase to high,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| MCH,decrease to low,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 1 | 1 |
| MCH, to normal or NC,n=1,1,4,4,4,3,4,8,3,6 | 1 | 1 | 4 | 4 | 3 | 3 | 1 | 5 | 2 | 5 |
| MCH,increase to high,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| MCHC,decrease to low,n=1,1,4,4,4,3,4,8,3,6 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 3 | 1 | 1 |
| MCHC, to normal or NC,n=1,1,4,4,4,3,4,8,3,6 | 1 | 0 | 4 | 3 | 4 | 2 | 3 | 5 | 2 | 5 |
| MCHC,increase to high,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| MCV,decrease to low,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 1 |
| MCV, to normal or NC,n=1,1,4,4,4,3,4,8,3,6 | 1 | 0 | 4 | 4 | 4 | 3 | 2 | 8 | 2 | 5 |
| MCV,increase to high,n=1,1,4,4,4,3,4,8,3,6 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mono,decrease to low,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Mono, to normal or NC,n=1,1,4,4,4,3,4,8,3,6 | 0 | 1 | 3 | 3 | 4 | 3 | 2 | 5 | 0 | 1 |
| Mono,increase to high,n=1,1,4,4,4,3,4,8,3,6 | 1 | 0 | 1 | 1 | 0 | 0 | 2 | 3 | 3 | 5 |
| Erythro,decrease to low,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Erythro, to normal or NC,n=1,1,4,4,4,3,4,8,3,6 | 1 | 1 | 4 | 4 | 4 | 3 | 3 | 6 | 2 | 6 |
| Erythro,increase to high,n=1,1,4,4,4,3,4,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Reticu,decrease to low,n=1,1,3,3,2,1,4,8,2,6 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 1 | 1 |
| Reticu,to normal or NC,n=1,1,3,3,2,1,4,8,2,6 | 1 | 1 | 1 | 3 | 1 | 0 | 1 | 4 | 1 | 4 |
| Reticu,increase to high,n=1,1,3,3,2,1,4,8,2,6 | 0 | 0 | 1 | 0 | 1 | 1 | 3 | 1 | 0 | 1 |
Blood samples were collected for the analysis of following hematology parameters: Baso, Eosino, Hct, MCHC, MCH, MCV, Mono, Erythro and Reticu. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data at worst-case post Baseline is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (MM) |
|---|---|
| Baso,decrease to low,n=35 | 0 |
| Baso, to normal or NC,n=35 | 33 |
| Baso,increase to high,n=35 | 2 |
| Eosino,decrease to low,n=35 | 7 |
| Eosino,to normal or NC,n=35 | 26 |
| Eosino,increase to high,n=35 | 2 |
| Hct,decrease to low,n=35 | 4 |
| Hct, to normal or NC,n=35 | 31 |
| Hct,increase to high,n=35 | 0 |
| MCH,decrease to low,n=35 | 7 |
| MCH, to normal or NC,n=35 | 28 |
| MCH,increase to high,n=35 | 1 |
| MCHC,decrease to low,n=35 | 5 |
| MCHC, to normal or NC,n=35 | 28 |
| MCHC,increase to high,n=35 | 2 |
| MCV,decrease to low,n=35 | 6 |
| MCV, to normal or NC,n=35 | 28 |
| MCV,increase to high,n=35 | 1 |
| Mono,decrease to low,n=35 | 4 |
| Mono, to normal or NC,n=35 | 18 |
| Mono,increase to high,n=35 | 14 |
| Erythro,decrease to low,n=35 | 2 |
| Erythro, to normal or NC,n=35 | 31 |
| Erythro,increase to high,n=35 | 2 |
| Reticu,decrease to low,n=28 | 10 |
| Reticu, to normal or NC,n=28 | 14 |
| Reticu,increase to high,n=28 | 8 |
Blood samples were collected for the analysis of following hematology parameters: Baso, Eosino, Hct, MCHC, MCH, MCV, Mono, Erythro and Reticu. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline. Data at worst-case post Baseline is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (NHL) |
|---|---|
| Baso,decrease to low,n=6 | 0 |
| Baso, to normal or NC,n=6 | 6 |
| Baso,increase to high,n=6 | 0 |
| Eosino,decrease to low,n=6 | 0 |
| Eosino,to normal or NC,n=6 | 6 |
| Eosino,increase to high,n=6 | 0 |
| Hct,decrease to low,n=6 | 1 |
| Hct, to normal or NC,n=6 | 5 |
| Hct,increase to high,n=6 | 0 |
| MCH,decrease to low,n=6 | 1 |
| MCH, to normal or NC,n=6 | 5 |
| MCH,increase to high,n=6 | 0 |
| MCHC,decrease to low,n=6 | 1 |
| MCHC, to normal or NC,n=6 | 5 |
| MCHC,increase to high,n=6 | 0 |
| MCV,decrease to low,n=6 | 2 |
| MCV, to normal or NC,n=6 | 4 |
| MCV,increase to high,n=6 | 0 |
| Mono,decrease to low,n=6 | 0 |
| Mono, to normal or NC,n=6 | 4 |
| Mono,increase to high,n=6 | 2 |
| Erythro,decrease to low,n=6 | 2 |
| Erythro, to normal or NC,n=6 | 4 |
| Erythro,increase to high,n=6 | 0 |
| Reticu,decrease to low,n=5 | 0 |
| Reticu, to normal or NC,n=5 | 4 |
| Reticu,increase to high,n=5 | 1 |
Urine samples were collected to assess urine occult blood (OB) and urine protein (Pro). The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB and no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ for urine Pro indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
| Participants | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| OB,No change/decreased, n=1,1,4,4,2,3,3,8,3,6 | 1 | 1 | 3 | 3 | 1 | 2 | 1 | 5 | 2 | 5 |
| OB,Increase to small, n=1,1,4,4,2,3,3,8,3,6 | 0 | 0 | 1 | 0 | 1 | 1 | 2 | 3 | 1 | 0 |
| OB,Increase to moderate, n=1,1,4,4,2,3,3,8,3,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| OB,Increase to large, n=1,1,4,4,2,3,3,8,3,6 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Pro,No change/decreased, n=1,1,4,3,2,3,4,5,3,5 | 1 | 0 | 3 | 3 | 2 | 1 | 3 | 1 | 1 | 1 |
| Pro,Increase to trace, n=1,1,4,3,2,3,4,5,3,5 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 4 | 2 | 1 |
| Pro,Increase to 1+, n=1,1,4,3,2,3,4,5,3,5 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Pro,Increase to 2+, n=1,1,4,3,2,3,4,5,3,5 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Pro,Increase to 3+, n=1,1,4,3,2,3,4,5,3,5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pro,Unknown, n=1,1,4,3,2,3,4,5,3,5 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Urine samples were collected to assess urine OB and urine Pro. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB and no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ for urine Pro indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (MM) |
|---|---|
| OB,No change/decreased, n=33 | 18 |
| OB,Increase to small, n=33 | 14 |
| OB,Increase to moderate, n=33 | 1 |
| OB,Increase to large, n=33 | 0 |
| Pro,No change/decreased, n=31 | 15 |
| Pro,Increase to trace, n=31 | 11 |
| Pro,Increase to 1+, n=31 | 1 |
| Pro,Increase to 2+, n=31 | 0 |
| Pro,Increase to 3+, n=31 | 0 |
| Pro,Unknown, n=31 | 4 |
Urine samples were collected to assess urine OB and urine Pro. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB. For Urine Pro., results were reported as no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (NHL) |
|---|---|
| OB,No change/decreased, n=5 | 4 |
| OB,Increase to small, n=5 | 0 |
| OB,Increase to moderate, n=5 | 0 |
| OB,Increase to large, n=5 | 1 |
| Pro,No change/decreased, n=4 | 3 |
| Pro,Increase to trace, n=4 | 1 |
| Pro,Increase to 1+, n=4 | 0 |
| Pro,Increase to 2+, n=4 | 0 |
| Pro,Increase to 3+, n=4 | 0 |
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
| Grams per day | Part 1: GSK2857916 0.06 mg/kg |
|---|---|
| Day 1 (Cycle 2) | -0.0 ± NA |
| Day 1 (Cycle 3) | 0.3 ± NA |
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
| Grams per day | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.03 mg/kg |
|---|---|---|
| Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.03 mg/kg and 0.12 mg/kg | 0.4 ± 0.72 | — |
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
| Grams per day | Part 1: GSK2857916 0.24 mg/kg |
|---|---|
| Day 1 (Cycle 2) | -0.0 ± NA |
| Day 1 (Cycle 3) | -0.0 ± NA |
| Day 1 (Cycle 4) | 88.1 ± NA |
| Day 1 (Cycle 5) | -0.1 ± NA |
| Day 1 (Cycle 6) | -0.0 ± NA |
| Day 1 (Cycle 7) | -0.0 ± NA |
| Day 1 (Cycle 8) | -0.1 ± NA |
| Day 1 (Cycle 9) | -0.1 ± NA |
| Day 1 (Cycle 10) | -0.1 ± NA |
| Day 1 (Cycle 12) | -0.1 ± NA |
| Day 1 (Cycle 13) | -0.1 ± NA |
| Day 1 (Cycle 14) | -0.1 ± NA |
| Day 1 (Cycle 15) | -0.1 ± NA |
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
| Grams per day | Part 1: GSK2857916 0.48 mg/kg |
|---|---|
| Day 1 (Cycle 2), n=2 | 0.0 ± 0.04 |
| Day 1 (Cycle 3), n=1 | 0.8 ± NA |
| Day 1 (Cycle 5), n=1 | 0.1 ± NA |
| Day 1 (Cycle 6), n=1 | 0.1 ± NA |
| Day 1 (Cycle 7), n=1 | 0.1 ± NA |
| Day 1 (Cycle 8), n=1 | 0.1 ± NA |
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
| Grams per day | Part 1: GSK2857916 0.96 mg/kg |
|---|---|
| Day 1 (Cycle 2), n=2 | 0.2 ± 0.35 |
| Day 1 (Cycle 3), n=2 | -0.1 ± 0.07 |
| Day 1 (Cycle 4), n=1 | -0.1 ± NA |
| Day 1 (Cycle 5), n=1 | 0.0 ± NA |
| Day 1 (Cycle 6), n=1 | 0.2 ± NA |
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
| Grams per day | Part 1: GSK2857916 1.92 mg/kg |
|---|---|
| Day 1 (Cycle 2), n=3 | -0.1 ± 0.48 |
| Day 1 (Cycle 3), n=3 | -30.3 ± 51.72 |
| Day 1 (Cycle 4), n=4 | -22.4 ± 45.06 |
| Day 1 (Cycle 5), n=3 | 0.2 ± 1.42 |
| Day 1 (Cycle 6), n=2 | -0.6 ± 0.99 |
| Day 1 (Cycle 7), n=2 | -0.6 ± 1.16 |
| Day 1 (Cycle 8), n=2 | -0.6 ± 1.06 |
| Day 1 (Cycle 11), n=1 | -1.4 ± NA |
| Day 1 (Cycle 12), n=1 | -1.4 ± NA |
| Day 1 (Cycle 13), n=1 | -1.4 ± NA |
| Day 1 (Cycle 14), n=1 | -1.4 ± NA |
| Day 1 (Cycle 16), n=1 | -1.3 ± NA |
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
| Grams per day | Part 1: GSK2857916 2.50 mg/kg |
|---|---|
| Day 1 (Cycle 2), n=4 | 0.8 ± 1.54 |
| Day 1 (Cycle 3), n=2 | -0.2 ± 0.31 |
| Day 1 (Cycle 4), n=2 | -0.2 ± 0.38 |
| Day 1 (Cycle 5), n=1 | 0.0 ± NA |
| Day 1 (Cycle 6), n=2 | -0.2 ± 0.33 |
| Day 1 (Cycle 7), n=1 | 0.2 ± NA |
| Day 1 (Cycle 8), n=1 | -0.5 ± NA |
| Day 1 (Cycle 10), n=1 | -0.4 ± NA |
| Day 1 (Cycle 12), n=1 | -0.5 ± NA |
| Day 1 (Cycle 13), n=1 | -0.5 ± NA |
| Day 1 (Cycle 14), n=1 | -0.4 ± NA |
| Day 1 (Cycle 15), n=1 | -0.5 ± NA |
| Day 1 (Cycle 16), n=1 | -0.5 ± NA |
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
| Grams per day | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|
| Day 1 (Cycle 2), n=2,5 | -0.6 ± 0.83 | 0.0 ± 0.45 |
| Day 1 (Cycle 3), n=2,4 | -0.6 ± 0.81 | -0.0 ± 0.23 |
| Day 1 (Cycle 4), n=2,4 | -0.7 ± 0.79 | -0.1 ± 0.25 |
| Day 1 (Cycle 5), n=2,4 | -0.6 ± 0.78 | -0.1 ± 0.46 |
| Day 1 (Cycle 6), n=2,4 | -0.6 ± 0.80 | -0.0 ± 0.33 |
| Day 1 (Cycle 7), n=2,4 | -0.6 ± 0.79 | -0.1 ± 0.48 |
| Day 1 (Cycle 8), n=2,2 | -0.6 ± 0.80 | 0.1 ± 0.15 |
| Day 1 (Cycle 9), n=1,2 | -1.1 ± NA | 0.2 ± 0.33 |
| Day 1 (Cycle 10), n=1,2 | -1.1 ± NA | -0.0 ± 0.03 |
| Day 1 (Cycle 11), n=1,2 | -1.2 ± NA | -0.1 ± 0.06 |
| Day 1 (Cycle 12), n=1,2 | -1.2 ± NA | 0.0 ± 0.13 |
| Day 1 (Cycle 13), n=1,2 | -1.1 ± NA | 0.0 ± 0.09 |
| Day 1 (Cycle 14), n=1,2 | -1.0 ± NA | 0.3 ± 0.11 |
| Day 1 (Cycle 15), n=1,2 | -1.1 ± NA | 0.1 ± 0.10 |
| Day 1 (Cycle 16), n=1,2 | -1.2 ± NA | 0.4 ± 0.11 |
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
| Grams per day | Part 2: GSK2857916 3.40 mg/kg (MM) |
|---|---|
| Day 1 (Cycle 2), n=24 | -0.5 ± 1.21 |
| Day 1 (Cycle 3), n=18 | -0.7 ± 1.29 |
| Day 1 (Cycle 4), n=13 | -0.7 ± 1.65 |
| Day 1 (Cycle 5), n=15 | -0.7 ± 1.66 |
| Day 1 (Cycle 6), n=14 | -0.8 ± 1.69 |
| Day 1 (Cycle 7), n=14 | -0.9 ± 1.56 |
| Day 1 (Cycle 8), n=16 | -0.7 ± 1.53 |
| Day 1 (Cycle 9), n=13 | -0.5 ± 1.01 |
| Day 1 (Cycle 10), n=12 | -0.4 ± 1.06 |
| Day 1 (Cycle 11), n=10 | -0.4 ± 1.01 |
| Day 1 (Cycle 12), n=10 | -0.4 ± 1.11 |
| Day 1 (Cycle 13), n=9 | -0.4 ± 1.27 |
| Day 1 (Cycle 14), n=9 | -0.4 ± 1.25 |
| Day 1 (Cycle 15), n=9 | -0.4 ± 1.30 |
| Day 1 (Cycle 16), n=9 | -0.3 ± 1.35 |
Urine samples were collected to assess urine Protein. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Protein excretion (24 hour) is presented.
| Grams per day | Part 2: GSK2857916 3.40 mg/kg (NHL) |
|---|---|
| Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (NHL) | 0.0 ± 0.18 |
Blood samples were collected at designated timepoints. Pharmacokinetic (PK) parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
| Hours*nanogram per milliliter | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1 | — | 215803.06 ± NA | 767285.51 ± 49.51 | 632339.28 ± 101.14 | 2991509.97 ± 72.12 | 9235256.20 ± 46.65 | 18469186.92 ± NA | — | 8355209.26 ± 25.29 |
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
No measurements were reported for this outcome.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
| Hours*nanogram per milliliter | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1 | — | 200467.82 ± NA | 633446.78 ± 35.42 | 729443.84 ± 91.22 | 2389114.19 ± 51.12 | 4448319.69 ± 79.51 | 9892863.42 ± 51.81 | 23121531.16 ± 6.59 | 9738914.76 ± 38.82 |
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
No measurements were reported for this outcome.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
| Hours*nanogram per milliliter | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve From Zero to Time of Last Quantifiable Concentration (AUC[0-tlast]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1 | 44260.79 ± NA | 178485.20 ± NA | 637783.48 ± 35.67 | 694825.13 ± 107.50 | 2170746.96 ± 59.81 | 4492292.65 ± 82.00 | 10093784.72 ± 54.20 | 19239850.61 ± 53.15 | 10131666.86 ± 47.32 |
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
No measurements were reported for this outcome.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
| Milliliter per hour | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Clearance (CL) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1 | — | 28.27 ± NA | 10.53 ± 58.94 | 25.01 ± 88.61 | 15.10 ± 75.16 | 8.46 ± 27.46 | 11.68 ± NA | — | 38.84 ± 37.53 |
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
No measurements were reported for this outcome.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
| Nanograms per milliliter | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1 | 429.00 ± NA | 1323.00 ± NA | 2956.77 ± 18.45 | 4548.10 ± 20.27 | 11876.46 ± 24.08 | 23050.05 ± 23.05 | 43774.18 ± 45.18 | 68128.02 ± 20.84 | 117385.57 ± 24.14 |
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
No measurements were reported for this outcome.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
| Nanograms per milliliter | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Day 1, Cycle 1,n=0,1,4,2,1,3,3,2,6 | — | NA ± NA | 381.95 ± 105.55 | 1331.11 ± 44.43 | 4307.00 ± NA | 3720.27 ± 113.71 | 11420.61 ± 35.70 | 28134.46 ± 35.97 | 2301.18 ± 75.69 |
| Day 1, Cycle 2,n=0,1,0,2,1,2,2,2,5 | — | NA ± NA | — | 1672.18 ± 28.76 | 7259.00 ± NA | 9510.04 ± 104.56 | 12791.83 ± 46.82 | 12719.77 ± 6.21 | 2643.94 ± 123.56 |
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
| Nanograms per milliliter | Part 1: GSK2857916 2.50 mg/kg |
|---|---|
| Day 1, Cycle 1,n=8 | 3726.78 ± 49.92 |
| Day 1, Cycle 2,n=4 | 11352.94 ± 268.64 |
| Day 1, Cycle 4,n=3 | 11121.73 ± 59.75 |
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
| Hours | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Terminal Half-life (t1/2) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1 | — | 126.18 ± NA | 188.20 ± 37.41 | 117.82 ± 76.00 | 198.48 ± 50.42 | 264.93 ± 46.73 | 308.39 ± NA | — | 103.74 ± 17.29 |
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
No measurements were reported for this outcome.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
| Milliliter | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Volume of Distribution at Steady State (Vss) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1 | — | 5239 ± NA | 2900 ± 29.04 | 4286 ± 31.29 | 4388 ± 21.99 | 3224 ± 22.37 | 5156 ± NA | — | 5215 ± 19.41 |
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
No measurements were reported for this outcome.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. Median and full range of Tmax have been presented.
| Hours | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Time to Reach Maximum Observed Concentration (Tmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1 | 2.080 (2.08 to 2.08) | 4.080 (4.08 to 4.08) | 1.185 (1.00 to 2.00) | 3.085 (2.00 to 8.78) | 1.000 (1.00 to 4.00) | 2.050 (2.00 to 2.08) | 1.000 (0.50 to 24.00) | 6.920 (2.02 to 8.78) | 1.560 (0.95 to 2.07) |
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. Median and full range of Tmax have been presented.
No measurements were reported for this outcome.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
| Nanograms per milliliter | Part 2: GSK2857916 3.40 mg/kg (MM) |
|---|---|
| Day 1, Cycle 1,n=28 | 3486.49 ± 85.71 |
| Day 1, Cycle 2,n=18 | 5799.89 ± 66.52 |
| Day 1, Cycle 4,n=12 | 6184.46 ± 103.79 |
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
| Nanograms per milliliter | Part 2: GSK2857916 3.40 mg/kg (NHL) |
|---|---|
| Cycle 1 Day 1, n=5 | 0.0 ± 0.00 |
| Cycle 2 Day 1, n=4 | 3761.8 ± 2225.57 |
| Cycle 3 Day 1, n=1 | 8401.0 ± NA |
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
| Hours*picogram per milliliter | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| AUC(0-tlast) of Cys Monomethyl Auristatin F (Cys-mcMMAF) Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1 | — | — | 1157.46 ± NA | 1623.87 ± 41.43 | 14681.62 ± 91.88 | 20787.48 ± 209.27 | 72608.00 ± 17.60 | 119177.30 ± 35.77 | 181147.61 ± 94.32 |
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.
No measurements were reported for this outcome.
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
| Picograms per milliliter | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Cmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1 | — | — | 51.50 ± NA | 91.49 ± 31.76 | 260.62 ± 15.70 | 488.29 ± 38.51 | 1054.02 ± 18.96 | 1199.86 ± 35.11 | 2544.02 ± 87.04 |
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.
No measurements were reported for this outcome.
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
| Picograms per milliliter | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Day 1, Cycle 1,n=0,1,4,2,1,3,3,2,6 | — | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Day 1, Cycle 2,n=0,1,0,2,1,2,2,2,5 | — | NA ± NA | — | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
| Picograms per milliliter | Part 1: GSK2857916 2.50 mg/kg |
|---|---|
| Day 1, Cycle 1,n=8 | NA ± NA |
| Day 1, Cycle 2,n=4 | NA ± NA |
| Day 1, Cycle 4,n=3 | NA ± NA |
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. Median and full range of Tmax have been presented.
| Hours | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|
| Tmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1 | — | — | 49.130 (49.13 to 49.13) | 23.875 (9.00 to 24.63) | 24.730 (24.00 to 25.83) | 9.050 (8.78 to 22.83) | 8.750 (7.75 to 24.00) | 23.700 (23.17 to 24.97) | 24.040 (7.83 to 25.00) |
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. Median and full range of Tmax have been presented.
No measurements were reported for this outcome.
Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated electrochemiluminescent (ECL) immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.
| Participants | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (MM) |
|---|---|
| Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (MM) | 0 |
Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated ECLimmunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (NHL) |
|---|---|
| Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (NHL) | 0 |
Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive (pos) samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative (neg) conclusive ADA results at Baseline and different timepoints is presented.
| Participants | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline,screening,pos, n=1,1,4,4,4,3,4,7,2,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline,screening,neg, n=1,1,4,4,4,3,4,7,2,6 | 1 | 1 | 4 | 4 | 4 | 3 | 4 | 7 | 2 | 6 |
| Baseline,neg,conclusive,n=1,1,4,4,4,3,4,7,2,6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 |
| Cycle 2 Day 1,screening,pos, n=0,1,4,2,2,3,3,8,3,5 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cycle 2 Day 1,screening,neg, n=0,1,4,2,2,3,3,8,3,5 | — | 1 | 4 | 2 | 2 | 3 | 3 | 8 | 3 | 5 |
| Cycle 2 Day 1,neg,conclusive,n=0,1,4,2,2,3,3,8,3,5 | — | 1 | 3 | 2 | 2 | 3 | 3 | 8 | 2 | 5 |
| Cycle 3 Day 1,screening,pos, n=0,1,0,2,2,1,2,4,3,6 | — | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cycle 3 Day 1,screening,neg, n=0,1,0,2,2,1,2,4,3,6 | — | 1 | — | 2 | 2 | 1 | 2 | 4 | 3 | 6 |
| Cycle 3 Day 1,neg,conclusive,n=0,1,0,2,2,1,2,4,3,6 | — | 1 | — | 2 | 2 | 1 | 2 | 2 | 0 | 4 |
| Cycle 4 Day 1,screening,pos, n=0,0,0,0,0,0,0,0,0,1 | — | — | — | — | — | — | — | — | — | 0 |
| Cycle 4 Day 1,screening,neg, n=0,0,0,0,0,0,0,0,0,1 | — | — | — | — | — | — | — | — | — | 1 |
| Cycle 4 Day 1,neg,conclusive,n=0,0,0,0,0,0,0,0,0,1 | — | — | — | — | — | — | — | — | — | 0 |
| Cycle 6 Day 1,screening,pos, n=0,0,0,1,1,1,2,3,3,3 | — | — | — | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Cycle 6 Day 1,screening,neg, n=0,0,0,1,1,1,2,3,3,3 | — | — | — | 1 | 1 | 1 | 2 | 3 | 2 | 3 |
| Cycle 6 Day 1,confirming,pos,n=0,0,0,0,0,0,0,0,1,0 | — | — | — | — | — | — | — | — | 0 | — |
| Cycle 6 Day 1,confirming,neg,n=0,0,0,0,0,0,0,0,1,0 | — | — | — | — | — | — | — | — | 1 | — |
| Cycle 6 Day 1,neg,conclusive,n=0,0,0,1,1,1,2,3,3,3 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cycle 9 Day 1,screening,pos, n=0,0,0,1,0,0,1,1,2,2 | — | — | — | 0 | — | — | 0 | 0 | 0 | 0 |
| Cycle 9 Day 1,screening,neg, n=0,0,0,1,0,0,1,1,2,2 | — | — | — | 1 | — | — | 1 | 1 | 2 | 2 |
| Cycle 9 Day 1,neg,conclusive,n=0,0,0,1,0,0,1,1,2,2 | — | — | — | 0 | — | — | 0 | 0 | 0 | 0 |
| Cycle 12 Day 1,screening,pos,n=0,0,0,1,0,0,1,1,1,3 | — | — | — | 0 | — | — | 0 | 0 | 0 | 1 |
| Cycle 12 Day 1,screening,neg,n=0,0,0,1,0,0,1,1,1,3 | — | — | — | 1 | — | — | 1 | 1 | 1 | 2 |
| Cycle 12 Day1,confirming,pos,n=0,0,0,0,0,0,0,0,0,1 | — | — | — | — | — | — | — | — | — | 0 |
| Cycle 12 Day1,confirming,neg,n=0,0,0,0,0,0,0,0,0,1 | — | — | — | — | — | — | — | — | — | 1 |
| Cycle 12 Day1,neg,conclusive,n=0,0,0,1,0,0,1,1,1,3 | — | — | — | 0 | — | — | 0 | 0 | 0 | 0 |
| Cycle 16 Day 1,screening,pos,n=0,0,0,0,0,0,1,1,1,2 | — | — | — | — | — | — | 0 | 0 | 0 | 0 |
| Cycle 16 Day 1,screening,neg,n=0,0,0,0,0,0,1,1,1,2 | — | — | — | — | — | — | 1 | 1 | 1 | 2 |
| Cycle 16 Day1,neg,conclusive,n=0,0,0,0,0,0,1,1,1,2 | — | — | — | — | — | — | 0 | 0 | 0 | 0 |
| End of study,screening,pos,n=1,1,4,4,4,3,3,6,1,5 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| End of study,screening,neg,n=1,1,4,4,4,3,3,6,1,5 | 1 | 1 | 4 | 3 | 4 | 3 | 3 | 6 | 1 | 5 |
| End of study,confirming,pos,n=0,0,0,1,0,0,0,0,0,0 | — | — | — | 0 | — | — | — | — | — | — |
| End of study,confirming,neg,n=0,0,0,1,0,0,0,0,0,0 | — | — | — | 1 | — | — | — | — | — | — |
| End of study,neg,conclusive,n=1,1,4,4,4,3,3,6,1,5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative conclusive ADA results at Baseline and different timepoints is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (MM) |
|---|---|
| Baseline, screening, positive, n=30 | 2 |
| Baseline, screening, negative n=30 | 28 |
| Baseline, confirming, positive, n=2 | 0 |
| Baseline, confirming, negative, n=2 | 2 |
| Baseline, negative, conclusive, n=30 | 21 |
| Cycle 2, Day 1, screening, positive, n=31 | 3 |
| Cycle 2, Day 1, screening, negative, n=31 | 28 |
| Cycle 2, Day 1, confirming, positive, n=3 | 0 |
| Cycle 2, Day 1, confirming, negative, n=3 | 3 |
| Cycle 2, Day 1, negative, conclusive, n=31 | 27 |
| Cycle 3, Day 1, screening, positive, n=23 | 0 |
| Cycle 3, Day 1, screening, negative, n=23 | 23 |
| Cycle 3, Day 1, negative, conclusive, n=23 | 14 |
| Cycle 6, Day 1, screening, positive, n=17 | 4 |
| Cycle 6, Day 1, screening, negative, n=17 | 13 |
| Cycle 6, Day 1, confirming, positive, n=4 | 0 |
| Cycle 6, Day 1, confirming, negative, n=4 | 4 |
| Cycle 6, Day 1, negative, conclusive, n=17 | 0 |
| Cycle 7, Day 1, screening, positive, n=1 | 0 |
| Cycle 7, Day 1, screening, negative, n=1 | 1 |
| Cycle 7, Day 1, negative, conclusive, n=1 | 0 |
| Cycle 9, Day 1, screening, positive, n=16 | 2 |
| Cycle 9, Day 1, screening, negative, n=16 | 14 |
| Cycle 9, Day 1, confirming, positive, n=2 | 0 |
| Cycle 9, Day 1, confirming, negative, n=2 | 2 |
| Cycle 9, Day 1, negative, conclusive, n=16 | 0 |
| Cycle 11, Day 1, screening, positive, n=1 | 0 |
| Cycle 11, Day 1, screening, negative, n=1 | 1 |
| Cycle 11, Day 1, negative, conclusive, n=1 | 0 |
| Cycle 12, Day 1, screening, positive, n=8 | 0 |
| Cycle 12, Day 1, screening, negative, n=8 | 8 |
| Cycle 12, Day 1, negative, conclusive, n=8 | 0 |
| Cycle 16, Day 1, screening, positive, n=8 | 0 |
| Cycle 16, Day 1, screening, negative, n=8 | 8 |
| Cycle 16, Day 1, negative, conclusive, n=8 | 0 |
| End of study, screening, positive, n=21 | 1 |
| End of study, screening, negative, n=21 | 20 |
| End of study, confirming, positive, n=1 | 0 |
| End of study, confirming, negative, n=1 | 1 |
| End of study, negative, conclusive, n=21 | 0 |
Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative conclusive ADA results at Baseline and different timepoints is presented.
| Participants | Part 2: GSK2857916 3.40 mg/kg (NHL) |
|---|---|
| Baseline, screening, positive, n=5 | 0 |
| Baseline, screening, negative n=5 | 5 |
| Baseline, negative, conclusive, n=5 | 5 |
| Cycle 2, Day 1, screening, positive, n=4 | 0 |
| Cycle 2, Day 1, screening, negative, n=4 | 4 |
| Cycle 2, Day 1, negative, conclusive, n=4 | 4 |
| Cycle 3, Day 1, screening, positive, n=2 | 1 |
| Cycle 3, Day 1, screening, negative, n=2 | 1 |
| Cycle 3, Day 1, confirming, positive, n=1 | 0 |
| Cycle 3, Day 1, confirming, negative, n=1 | 1 |
| Cycle 3, Day 1, negative, conclusive, n=2 | 1 |
| End of study, screening, positive, n=4 | 0 |
| End of study, screening, negative, n=4 | 4 |
| End of study, negative, conclusive, n=4 | 0 |
ORR was determined by the investigator according to international myeloma working group uniform response criteria for MM (IMWG 2011). ORR was calculated as the number of participants with best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) and partial response (PR).
| Participants | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| Overall Response Rate (ORR)- Part 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 3 |
ORR was determined by the investigator according to IMWG 2011 uniform response criteria for MM. ORR was calculated as the number of participants with best overall response of sCR, CR, VGPR and PR.
| Participants | Part 2: GSK2857916 3.40 mg/kg (MM) |
|---|---|
| ORR-Part 2 (MM) | 21 |
Overall Response Rate in NHL population was determined by the investigator according to Revised Response Criteria for Malignant Lymphoma. ORR was calculated as the number of participants with confirmed complete remission (CR) or partial remission (PR). Complete remission was defined as disappearance of all evidence of disease and partial remission was defined as regression of measurable disease and no new sites.
| Participants | Part 2: GSK2857916 3.40 mg/kg (NHL) |
|---|---|
| ORR-Part 2 (NHL) | 0 |
CBR was calculated as the number of participants with best overall response of sCR, CR, VGPR, PR and minimal response (MR).
| Participants | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Benefit Rate (CBR)- Part 1 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 3 | 5 |
CBR was calculated as the number of participants with best overall response of sCR, CR, VGPR, PR and MR.
| Participants | Part 2: GSK2857916 3.40 mg/kg (MM) |
|---|---|
| CBR- Part 2 | 21 |
Collected over SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: GSK2857916 0.03 mg/kg | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Part 1: GSK2857916 0.06 mg/kg | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Part 1: GSK2857916 0.12 mg/kg | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Part 1: GSK2857916 0.24 mg/kg | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Part 1: GSK2857916 0.48 mg/kg | 0/4 (0%) | 1/4 (25%) | 3/4 (75%) |
| Part 1: GSK2857916 0.96 mg/kg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Part 1: GSK2857916 1.92 mg/kg | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| Part 1: GSK2857916 2.50 mg/kg | 1/8 (12.5%) | 4/8 (50%) | 8/8 (100%) |
| Part 1: GSK2857916 3.40 mg/kg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 1: GSK2857916 4.60 mg/kg | 1/6 (16.7%) | 3/6 (50%) | 6/6 (100%) |
| Part 2: GSK2857916 3.40 mg/kg (MM) | 5/35 (14.3%) | 17/35 (48.6%) | 35/35 (100%) |
| Part 2: GSK2857916 3.40 mg/kg (NHL) | 3/6 (50%) | 3/6 (50%) | 6/6 (100%) |
| Event | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg | Part 2: GSK2857916 3.40 mg/kg (MM) | Part 2: GSK2857916 3.40 mg/kg (NHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharyngeal haemorrhageRespiratory, thoracic and mediastinal disorders | 0/1 | 0/1 | 0/4 | 0/4 | 0/4 | 0/3 | 0/4 | 0/8 | 1/3 | 0/6 | 0/35 | 0/6 |
| PneumoniaInfections and infestations | 0/1 | 0/1 | 0/4 | 0/4 | 0/4 | 0/3 | 0/4 | 1/8 | 1/3 | 0/6 | 5/35 | 0/6 |
| Hyperviscosity syndromeBlood and lymphatic system disorders | 0/1 | 0/1 | 1/4 | 0/4 | 0/4 | 0/3 | 0/4 | 0/8 | 0/3 | 0/6 | 0/35 | 0/6 |
| HypotensionVascular disorders | 0/1 | 0/1 | 0/4 | 1/4 | 0/4 | 0/3 | 0/4 | 0/8 | 0/3 | 0/6 | 0/35 | 0/6 |
| Limbal stem cell deficiencyEye disorders | 0/1 | 0/1 | 0/4 | 0/4 | 0/4 | 0/3 | 1/4 | 0/8 | 0/3 | 0/6 | 0/35 | 0/6 |
| NauseaGastrointestinal disorders | 0/1 | 0/1 | 0/4 | 0/4 | 1/4 | 0/3 | 0/4 | 0/8 | 0/3 | 0/6 | 0/35 | 0/6 |
| PyrexiaGeneral disorders | 0/1 | 0/1 | 0/4 | 1/4 | 0/4 | 0/3 | 0/4 | 0/8 | 0/3 | 1/6 | 1/35 | 0/6 |
| Spinal cord compressionNervous system disorders | 0/1 | 0/1 | 0/4 | 0/4 | 0/4 | 0/3 | 1/4 | 0/8 | 0/3 | 0/6 | 0/35 | 0/6 |
| VomitingGastrointestinal disorders | 0/1 | 0/1 | 0/4 | 0/4 | 1/4 | 0/3 | 0/4 | 0/8 | 0/3 | 0/6 | 0/35 | 0/6 |
| BabesiosisInfections and infestations | 0/1 | 0/1 | 0/4 | 0/4 | 0/4 | 0/3 | 0/4 | 0/8 | 0/3 | 1/6 | 0/35 | 0/6 |
| Event | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg | Part 2: GSK2857916 3.40 mg/kg (MM) | Part 2: GSK2857916 3.40 mg/kg (NHL) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/1 | 1/1 | 1/4 | 1/4 | 0/4 | 2/3 | 1/4 | 3/8 | 0/3 | 3/6 | 10/35 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 0/1 | 1/1 | 1/4 | 0/4 | 0/4 | 0/3 | 0/4 | 1/8 | 1/3 | 1/6 | 10/35 | 1/6 |
| FatigueGeneral disorders | 1/1 | 0/1 | 1/4 | 2/4 | 1/4 | 2/3 | 1/4 | 3/8 | 2/3 | 4/6 | 8/35 | 1/6 |
| HyperuricaemiaMetabolism and nutrition disorders | 0/1 | 1/1 | 0/4 | 0/4 | 0/4 | 0/3 | 0/4 | 0/8 | 0/3 | 0/6 | 0/35 | 0/6 |
| NeutropeniaBlood and lymphatic system disorders | 1/1 | 1/1 | 1/4 | 1/4 | 0/4 | 0/3 | 0/4 | 1/8 | 0/3 | 1/6 | 2/35 | 0/6 |
| Osteonecrosis of jawMusculoskeletal and connective tissue disorders | 1/1 | 0/1 | 0/4 | 0/4 | 0/4 | 0/3 | 0/4 | 0/8 | 0/3 | 0/6 | 0/35 | 0/6 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/1 | 1/1 | 1/4 | 1/4 | 1/4 | 0/3 | 1/4 | 1/8 | 2/3 | 5/6 | 9/35 | 0/6 |
| Vision blurredEye disorders | 0/1 | 0/1 | 0/4 | 0/4 | 0/4 | 0/3 | 3/4 | 2/8 | 3/3 | 4/6 | 18/35 | 2/6 |
| VomitingGastrointestinal disorders | 0/1 | 1/1 | 0/4 | 0/4 | 0/4 | 0/3 | 0/4 | 0/8 | 1/3 | 2/6 | 2/35 | 0/6 |
| NauseaGastrointestinal disorders | 0/1 | 0/1 | 2/4 | 2/4 | 1/4 | 0/3 | 3/4 | 3/8 | 2/3 | 4/6 | 11/35 | 1/6 |
| Age, Continuous(years) | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg | Part 2: GSK2857916 3.40 mg/kg (MM) | Part 2: GSK2857916 3.40 mg/kg (NHL) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 49.0 ± NA | 71.0 ± NA | 56.5 ± 3.32 | 58.5 ± 8.35 | 60.0 ± 10.89 | 58.7 ± 13.05 | 65.3 ± 4.79 | 62.6 ± 11.04 | 48.0 ± 8.19 | 54.8 ± 10.11 | 60.5 ± 7.93 | 60.2 ± 9.81 | 59.6 ± 8.90 |
| Sex: Female, Male(Participants) | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg | Part 2: GSK2857916 3.40 mg/kg (MM) | Part 2: GSK2857916 3.40 mg/kg (NHL) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 0 | 3 | 2 | 2 | 1 | 2 | 5 | 1 | 1 | 18 | 3 | 39 |
| Male | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 2 | 5 | 17 | 3 | 40 |
| Race/Ethnicity, Customized(Participants) | Part 1: GSK2857916 0.03 mg/kg | Part 1: GSK2857916 0.06 mg/kg | Part 1: GSK2857916 0.12 mg/kg | Part 1: GSK2857916 0.24 mg/kg | Part 1: GSK2857916 0.48 mg/kg | Part 1: GSK2857916 0.96 mg/kg | Part 1: GSK2857916 1.92 mg/kg | Part 1: GSK2857916 2.50 mg/kg | Part 1: GSK2857916 3.40 mg/kg | Part 1: GSK2857916 4.60 mg/kg | Part 2: GSK2857916 3.40 mg/kg (MM) | Part 2: GSK2857916 3.40 mg/kg (NHL) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Race — Black or African American | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 4 | 0 | 0 | 5 | 0 | 10 |
| Race — Arabic/North African Heritage | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 2 |
| Race — White/Caucasian/European Heritage | 1 | 1 | 4 | 3 | 4 | 3 | 3 | 4 | 3 | 5 | 28 | 6 | 65 |
| Race — Japanese Heritage | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Race — South East Asian Heritage | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Jul 2014 to primary completion in Aug 2018, 49 months.
Results were first posted in Sep 2019, 1 year after primary completion.
Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 49 months is above that.
Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belantamab mafodotin